Novel 1-aza bicycloalkyl derivatives for the treatment of psychotic and neurodegenerative disorders

Details for Australian Patent Application No. 2006303453 (hide)

Owner Novartis AG

Inventors Roy, Bernard Lucien; Marzi, Martin; Frederiksen, Mathias; Feuerbach, Dominik

Agent Davies Collison Cave

Pub. Number AU-B-2006303453

PCT Pub. Number WO2007/045478

Priority 0521508.2 21.10.05 GB

Filing date 19 October 2006

Wipo publication date 26 April 2007

Acceptance publication date 14 July 2011

International Classifications

C07D 453/02 (2006.01) Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids

A61K 31/435 (2006.01) - having six-membered rings with one nitrogen as the only ring hetero atom

A61P 25/00 (2006.01) Drugs for disorders of the nervous system

Event Publications

1 May 2008 PCT application entered the National Phase

  PCT publication WO2007/045478 Priority application(s): WO2007/045478

14 July 2011 Application Accepted

  Published as AU-B-2006303453

10 November 2011 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006303466-Automated packing system and method for chromatography columns

2006303452-Human antibodies against IL13 and therapeutic uses